SCHEMBL18509455

SCHEMBL18509455

Cc1nc2cccc(CCNC(=O)c3ccc(SC(F)(F)F)cc3)c2c(=O)n1C1CCC(=O)NC1=O

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 14/20 0.52
DDB1 Q16531 9/20 0.52
TNF P01375 1/20 0.52
IL1B P01584 1/20 0.52
IKZF3 Q9UKT9 1/20 0.52
CSNK1A1 P48729 1/20 0.41
IKZF1 Q13422 1/20 0.41
CHRM4 P08173 1/20 0.39
EPHX2 P34913 1/20 0.35
NR1H4 Q96RI1 1/20 0.35
CA2 P00918 2/20 0.35
JAK2 O60674 1/20 0.34
HDAC1 Q13547 3/20 0.34
HDAC2 Q92769 2/20 0.34
HDAC6 Q9UBN7 2/20 0.34
BRD4 O60885 1/20 0.34
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
NCOR2 Q9Y618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL283343 0.92 CRBN (0.54) CRBNDDB1TNFIL1BIKZF3
SCHEMBL12638481 0.86 CRBN (0.46) CRBNDDB1TNFIL1BIKZF3
SCHEMBL282990 0.84 CRBN (0.56) CRBNDDB1TNFIL1BIKZF3
SCHEMBL19732530 0.83 CRBN (0.50) CRBNDDB1TNFIL1BIKZF3
SCHEMBL282665 0.82 CRBN (0.59) CRBNDDB1TNFIL1BIKZF3
SCHEMBL283366 0.81 CRBN (0.53) CRBNDDB1TNFIL1BIKZF3
SCHEMBL18509457 0.81 CRBN (0.53) CRBNDDB1TNFIL1BIKZF3
SCHEMBL283159 0.81 CRBN (0.60) CRBNDDB1TNFIL1BIKZF3
SCHEMBL328464 0.81 CRBN (0.56) CRBNDDB1TNFIL1BIKZF3
SCHEMBL282762 0.80 CRBN (0.58) CRBNDDB1TNFIL1BIKZF3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3925609-A1 METHODS OF TREATING MULTIPLE MYELOMA WITH IMMUNOMODULATORY COMPOUNDS IN COMBINATION WITH ANTIBODIES Celgene Corporation (US) 2021-12-22 EP disclosed
EP-2428513-B1 5-substituted quinazolinone derivatives as anti-cancer agents CELGENE CORP (US) 2017-05-31 EP disclosed
EP-2420498-B1 5-substituted quinazolinone derivatives as anti-cancer agents CELGENE CORP (US) 2017-05-31 EP disclosed
WO-2017027672-A1 METHODS FOR TREATING SOLID TUMORS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES CELGENE CORPORATION (US) 2017-02-16 WO disclosed